Option Investor
Newsletter

Additional recommendations for our December Expirations

HAVING TROUBLE PRINTING?
Printer friendly version

The following three (3) put writes are being
recommended to add to our December positions

We are recommending puts in the following thee (3) companies:

LIFC - LifeCell Corporation
engages in the development and marketing of human-derived tissue-based products for use in reconstructive, urogynecologic, and orthopedic surgical procedures to repair soft tissue defects. It develops regenerative human tissue matrix, a three-dimensional structure that contains vascular channels, proteins, and growth factor binding sites, which provide a template for the regeneration of normal human tissue.


LEXR - Lexar Media, Inc.
engages in the design, development, manufacture, and marketing of digital media and other flash based storage products for consumer markets that utilize digital media for the capture and retrieval of digital content. It also offers a line of digital music players and portable data storage devices, as well as various connectivity products that link its media products to personal computers and other electronic host devices.


PTIE - Pain Therapeutics, Inc., a development stage company, engages in the development of drugs for use in pain management, principally in the area of opioid painkillers. The company's clinical pipeline comprises three proprietary drug candidates, which include Oxytrex, an oral opioid painkiller that is in two Phase III clinical trials for the treatment of severe chronic pain; PTI-901, which is in two Phase III clinical trials to treat men and women with irritable bowel syndrome; and Remoxy, an anti-abuse version of long-acting oxycodone that is in one Phase III clinical trial. It has research and collaboration agreement with Durect Corporation. Pain Therapeutics has a strategic alliance with King Pharmaceuticals, Inc. to develop and commercialize Remoxy and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in South San Francisco, California.


We are adding the following put writes below to our December Recommended list.

SELL LIFC Dec SYM: QKL-XW
Target Price $40.00 17.5 Put
Potential Profit(10 x = $400.00
Initial Margin $4,400 10 (contracts)
Return on Investment 9.09%
Cost Basis in Stock = $17.10
Days to Expiration = 26


SELL LEXR Dec SYM: EQG-XU
Target Price $25.00 7.5 Put
Potential Profit(10 x = $250.00
Initial Margin $1,912 10 (contracts)
Return on Investment 13.08%
Cost Basis in Stock = $7.25
Days to Expiration = 26

SELL PTIE Dec SYM: UQ-XU
Target Price $30.00 7.5 Put
Potential Profit(10 x = $300.00
Initial Margin $1,986 10 (contracts)
Return on Investment 15.11%
Cost Basis in Stock = $7.20
Days to Expiration = 26

Option Writers Newsletter Archives